演題詳細

ポスター / Poster

ポスター 26 (Poster 26) :B細胞性リンパ腫:Chemotherapy

print

日程
2013年10月11日(金)
時間
16:50 - 17:50
会場
ポスター会場 / Poster (ロイトン札幌 3F ロイトンホールABCD)
座長・司会
塚本 憲史 (Norifumi Tsukamoto):1
1:群馬大学医学部附属病院 腫瘍センター
 
前へ戻る

Varicella after treatment with bendamustine for malignant lymphoma

演題番号 : PS-1-194

籠尾 壽哉 (Toshiya Kagoo):1、米田 美栄 (Mie Yoneda):1、細田 亮 (Toru Hosoda):1、大橋 晃太 (Kota Ohashi):1、横山 明宏 (Akihiro Yokoyama):1、朴 載源 (Saigen Boku):1、矢野 尊啓 (Takahiro Yano):1、上野 博則 (Hironori Ueno):1

1:National Hospital Organization Tokyo Medical Center, Tokyo, Japan

 

Although bendamustine has increasingly been used for the treatment of indolent B cell non-Hodgkin lymphomas (B-NHL), there are several reports describing the association of its use with severe cytopenia and infectious complication. We report three cases of varicella after bendamustine therapy. An underlying lymphoma was splenic marginal zone lymphoma, Hodgkin lymphoma, and diffuse large B cell lymphoma in one each patient. All three had a past history of varicella, indicating reactivation of the virus. All patients were treated previously with more than 2 chemotherapy regimens. The patient with Hodgkin lymphoma was receiving mizoribine regularly for an autoimmune disease. None was treated with fludarabine-containing regimen. Pretreatment peripheral blood lymphocyte counts were low, median at 612/ μ L (range:208-1029). All were given prophylactic acyclovir. One patient developed varicella 270 days after the initial dose of bendamustine, another after one cycle of bendamustine. Peripheral blood lymphocyte counts at the onset of varicella was very low, median at 120/ μ L (range:60-260). Acyclovir was very effective, but bendamustine treatment had to be discontinued in all three. Bendamustine treatment of malignant lymphoma occasionally results in severe and persistent lymphocytopenia, which could predispose the patients to severe viral infection such as varicella.

前へ戻る